Ophthalmic Drugs Already Lead Medicare Part B Cost Drivers: How Will Gene Therapy Fit?

 
• By Cathy Kelly

Gene therapy for wet age-related macular degeneration is one of two later-stage gene therapies flagged in CVS Caremark’s latest pipeline report that are outliers because they target conditions afflicting millions of patients and could dramatically increase Part B spending.    

Ophthalmic drugs are A Growing Treatment Category. • Source: Shutterstock

More from Market Access

More from Pink Sheet